Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1623 1654
This examiner grants 60% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18293978 | CYANOPYRIDINE AND CYANOPYRIMIDINE BCL6 DEGRADERS | Non-Final OA | DANA-FARBER CANCER INSTITUTE, INC. |
| 17787828 | Protein Tyrosine Phosphatase Degraders and Methods of Use Thereof | Non-Final OA | ABBVIE INC. |
| 17311448 | COMPOSITIONS AND METHODS RELATED TO SITE-SPECIFIC IDENTIFICATION OF RNA MODIFICATIONS | Non-Final OA | The University of Chicago |
| 18044232 | FGFR INHIBITOR COMBINATION THERAPIES | Final Rejection | JANSSEN PHARMACEUTICA NV |
| 18158717 | USE OF NON-STEROIDAL ANTI-INFLAMMATORY COMPOUNDS FOR TREATMENT OF INFLAMMATION | Non-Final OA | University of Houston System |
| 17991482 | COMBINATION THERAPY COMPRISING AN FGFR INHIBITOR AND A KRAS INHIBITOR | Final Rejection | Incyte Corporation |
| 18286446 | COMPOSITION FOR PROMOTING LIPOLYSIS | Non-Final OA | SUNTORY HOLDINGS LIMITED |
| 18223768 | Heteroaryl Compounds as Ligand Directed Degraders of IRAK4 | Non-Final OA | Celgene Corporation |
| 17904419 | DRG-MDM2-2 FOR USE AS A NOVEL MOUSE DOUBLE MINUTE 2 (MDM2) INHIBITOR | Non-Final OA | ISTANBUL TEKNIK UNIVERSITESI |
| 17766200 | TREATMENT OF EOSINOPHILIC DISORDERS WITH AVAPRITINIB | Non-Final OA | Blueprint Medicines Corporation |
| 17786355 | 1H-PYRAZOLO[3,4-D]PYRIMIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF PLATINUM-RESISTANT CANCER | Non-Final OA | IMPERIAL COLLEGE INNOVATIONS LIMITED |
| 18286469 | COMPOSITIONS AND METHODS FOR TREATING CANCER | Non-Final OA | ONCOCUBE THERAPEUTICS LLC |
| 18376020 | SUBSTITUTED AMIDE MACROCYCLIC COMPOUNDS WITH OREXIN-2 RECEPTOR AGONIST ACTIVITY | Non-Final OA | Alkermes, Inc. |
| 17766832 | ARYL HETEROCYCLIC COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | Final Rejection | D. E. Shaw Research, LLC |
| 18374326 | INHIBITORS OF POSITIVE STRAND RNA VIRUSES | Non-Final OA | National Health Research Institutes |
| 18372753 | METHODS AND COMPOSITIONS FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS | Non-Final OA | Amylyx Pharmaceuticals, Inc. |
| 18107619 | PHARMACEUTICAL COMBINATION OF ANTISPASMODIC AND ANXIOLYTIC AGENT | Non-Final OA | Sushma Paul BERLIA |
| 18268359 | BTK DEGRADER | Non-Final OA | Newave Pharmaceutical Inc. |
| 17615673 | COMPOSITIONS AND METHODS FOR TREATING CENTRAL NERVOUS SYSTEM DISORDERS | Final Rejection | PaxMedica, Inc. |
| 18044270 | COMPOUND FOR USE IN THE TREATMENT OF DRY MOUTH | Final Rejection | ASAHI PHARMA CO., LTD. |
| 17995700 | TREATMENT FOR SEPSIS-INDUCED ORGAN DYSFUNCTION | Non-Final OA | Rinaldo Bellomo |
| 17906375 | TREATMENT OF SYMPTOMATIC VIRAL DISEASES | Non-Final OA | SYNACT PHARMA ApS |
| 17776273 | METHODS AND COMPOSITIONS FOR TREATMENT OF SOLID TUMORS USING F16 ISOINDOLE SMALL MOLECULES | Non-Final OA | Nova Southeastern University |
| 17754200 | PHARMACEUTICAL COMPOUNDS | Non-Final OA | SENTINEL ONCOLOGY LIMITED |
| 17337358 | RADIOIMMUNOCONJUGATES AND DNA DAMAGE AND REPAIR INHIBITOR COMBINATION THERAPY | Final Rejection | Fusion Pharmaceuticals Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy